Pharmanutra S.p.A.

Equities

PHN

IT0005274094

Pharmaceuticals

Market Closed - Borsa Italiana 11:44:59 2024-04-29 am EDT 5-day change 1st Jan Change
54 EUR +1.31% Intraday chart for Pharmanutra S.p.A. +2.47% -4.26%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lists in green except Mib; banks good AN
Iveco down on Mib; European stock exchanges in green AN
Futures await bourses up; China holds rates AN
Mib closes bullish; Terna takes top spot AN
PharmaNutra Gets Approvals to Merge Subsidiaries MT
PharmaNutra approves merger of Junia Pharma and Alesco AN
Futures passive; BoJ abandons negative rates. AN
Milan at parity; De Nora on bottom after accounts AN
PharmaNutra increases revenues to double digits in 2023 AN
Pharmanutra S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mib at peak since 2008; MPS updates annual max AN
Mib rallying; Saipem still bullish after accounts AN
Mib bearish; spotlight on US PCE data AN
Global markets live: Chevron, Expedia, Standard Chartered, Broadcom, Meta Platforms... Our Logo
Mib bullish above 32,700; Saipem on top AN
Europeans above parity; accounts push Campari AN
Indices up against expectations; Moncler recovers AN
PharmaNutra Approves Absorption of Two Units to Improve Group's Management Efficiency MT
PharmaNutra incorporates subsidiaries Junia Pharma and Alesco AN
Indices down; Italian inflation at 5.7 percent in 2023 AN
Stock markets in the red in Europe; Mib above 30,100 threshold AN
Futures down; Trump wins Iowa caucus AN
Mib bearish; Piaggio shines on cadet segment AN
Stock markets down; Germany's GDP contracts in 2023 AN
Stock markets in green with little momentum; banks down on Mib. AN
Chart Pharmanutra S.p.A.
More charts
Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
53.3 EUR
Average target price
80.67 EUR
Spread / Average Target
+51.34%
Consensus
  1. Stock Market
  2. Equities
  3. PHN Stock
  4. News Pharmanutra S.p.A.
  5. PharmaNutra Gets Approvals to Merge Subsidiaries